Milestones - About Us - 心通医疗

About Us

Milestones

2009-2013

Commenced early feasibility study for VitaFlow^® in 2009

2014

Commenced the pivotal clinical trial for VitaFlow^®

2015

Completed the first implantation of VitaFlow^® for pivotal clinical trial in China

Established Shanghai MicroPort CardioFlow Medtech Corporation

Commenced feasibility study for VitaFlow Liberty^®

2016

Completed the pivotal clinical trial enrollment for VitaFlow^® in China

VitaFlow^® was admitted into the “Green Path” for Innovative Medical Device by the NMPA

2017

Commenced the Registration Clinical Trial for VitaFlow Liberty^®in China

Achieved primary endpoints of the clinical trial in China for VitaFlow^®

Pre-IPO Investment(series B)

2018

Summitted VitaFlow^® registration application to the NMPA

Completed the first implantation of VitaFlow Liberty^® for registered clinical trial in China

VitaFlow Liberty^®was admitted into the “Green Path” for Innovative Medical Device by the NMPA

2019

Obtained NMPA approval for VitaFlow^®

Pre-IPO Investment(series C)

2020

Obtained approval for VitaFlow^® and Alwide^® in Argentina

Obtained approval for VitaFlow^®and Alwide^® in Thailand

Pre-IPO Investment (series D)

2021

CardioFlow was listed on the Main Board of the Hong Kong Stock Exchange

Obtained NMPA approval for VitaFlow Liberty^®, Alwide^®Plus and Angelguide^®

Completed the first overseas commercial implantation of VitaFlow^® in Argentina

Obtained approval for VitaFlow Liberty^® in Argentina

2022

Obtained approval for VitaFlow Liberty^®, Alwide^® Plus and Angelguide^® in Argentina

Completed the first implantation of VitaFlow Liberty^®in Colombia

Completed the first implantation of self-developed TMVR system in China

Obtained approval for Alwide^® Plus and Angelguide^® in Brazil

Obtained approval for Alwide^® Plus in Argentina

2023

Obtained approval for VitaFlow Liberty^® in Thailand, Russia, and Indonesia

Obtained approval for Alwide^®Plus in Thailand, Russia, Indonesia, Saudi Arabia, and Hong Kong, China

Completed the first implantation of VitaFlow Liberty^® in Thailand

Completed several pre-market human implantations of VitaFlow Liberty^® in Europe

Launched the first clinical application of VitaFlow^®III in China

Obtained NMPA approval for AccuSniper^TM

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.